GlassScriptPhysician profile
David A Bader
NPI 1154376143
$3,140.90
in general payments reported to CMS, 2019-2025
30 companies · $526 in 2025
The $526 reported for 2025 was more than what 80% of Diagnostic Radiology providers received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $147 · 2021: $64.98 · 2022: $510 · 2023: $728 · 2024: $758 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,012.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $462.90 | 2020-2025 | Imfinzi, Enhertu, Tagrisso |
| Eisai INC. | $387.62 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $314.88 | 2019-2023 | Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $254.36 | 2020-2025 | |
| Seagen INC. | $245.02 | 2019-2023 | Padcev |
| Merck Sharp & Dohme LLC | $202.89 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Ge Healthcare | $155.48 | 2022-2023 | |
| Exelixis INC. | $120.03 | 2022-2023 | Cabometyx |
| Mirati Therapeutics, INC. | $94.14 | 2024 | Krazati |
| Incyte Corporation | $92.86 | 2019-2023 | Jakafi |
| Beigene USA, INC. | $79.35 | 2024 | Brukinsa |
| Janssen Biotech, INC. | $75.19 | 2019-2025 | Erleada, Akeega |
| Amgen INC. | $66.03 | 2021-2022 | |
| Geron Corporation | $61.12 | 2024-2025 | Rytelo |
| Takeda Pharmaceuticals U.S.A., INC. | $59.97 | 2021-2023 | Fruzaqla |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $59.66 | 2023-2024 | Trodelvy |
| Medtronic, INC. | $46.47 | 2023 | Azure Xt Dr Mri Surescan |
| Pfizer INC. | $44.93 | 2019-2024 | |
| Glaxosmithkline, LLC. | $34.70 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $33.64 | 2024 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $29.96 | 2022 | |
| Karyopharm Therapeutics INC. | $28.57 | 2025 | Xpovio |
| Alexion Pharmaceuticals, INC. | $27.27 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.79 | 2019 | |
| Servier Pharmaceuticals LLC | $24.98 | 2025 | |
| Cti Biopharma Corp. | $24.97 | 2023 | Vonjo |
| Myovant Sciences INC. | $24.09 | 2022 | |
| Astellas Pharma US INC | $23.14 | 2022 | |
| Celgene Corporation | $22.82 | 2019 | |
| Lilly USA, LLC | $17.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.